BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

Related Keywords

Germany ,France ,United States ,Berlin ,Italy ,Jeff Ajer ,Traci Mccarty ,Andrew Villani ,Robert Klamroth ,Vivantes Klinikum ,Biomarin Pharmaceutical Inc ,Prnewswire Biomarin Pharmaceutical Inc ,Nasdaq ,Exchange Commission ,First Person Treated ,Reimbursement Discussions ,Commercially Available ,Marin Pharmaceutical ,Activities Accelerating ,Eligibility Testing ,About Hemophilia ,Biomarin Pharmaceutical ,Common Adverse Reactions ,Reproductive Potential ,Prescribing Information ,Important Safety ,Quarterly Report ,Biotechnology ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,